Menu
GWAS Study

Deciphering the genetics and mechanisms of predisposition to multiple myeloma.

Went M, Duran-Lozano L, Halldorsson GH et al.

39103364 PubMed ID
GWAS Study Type
377127 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

WM
Went M
DL
Duran-Lozano L
HG
Halldorsson GH
GA
Gunnell A
UN
Ugidos-Damboriena N
LP
Law P
EL
Ekdahl L
SA
Sud A
TG
Thorleifsson G
TM
Thodberg M
OT
Olafsdottir T
LA
Lamarca-Arrizabalaga A
CC
Cafaro C
NA
Niroula A
AR
Ajore R
LD
Lopez de Lapuente Portilla A
AZ
Ali Z
PM
Pertesi M
GH
Goldschmidt H
SL
Stefansdottir L
KS
Kristinsson SY
SS
Stacey SN
LT
Love TJ
RS
Rognvaldsson S
HR
Hajek R
VP
Vodicka P
PU
Pettersson-Kymmer U
SF
Späth F
SC
Schinke C
VR
Van Rhee F
SP
Sulem P
FE
Ferkingstad E
HE
Hjorleifsson Eldjarn G
MU
Mellqvist UH
JI
Jonsdottir I
MG
Morgan G
SP
Sonneveld P
WA
Waage A
WN
Weinhold N
TH
Thomsen H
FA
Försti A
HM
Hansson M
JA
Juul-Vangsted A
TU
Thorsteinsdottir U
HK
Hemminki K
KM
Kaiser M
RT
Rafnar T
SK
Stefansson K
HR
Houlston R
NB
Nilsson B
Chapter II

Abstract

Summary of the research findings

Multiple myeloma (MM) is an incurable malignancy of plasma cells. Epidemiological studies indicate a substantial heritable component, but the underlying mechanisms remain unclear. Here, in a genome-wide association study totaling 10,906 cases and 366,221 controls, we identify 35 MM risk loci, 12 of which are novel. Through functional fine-mapping and Mendelian randomization, we uncover two causal mechanisms for inherited MM risk: longer telomeres; and elevated levels of B-cell maturation antigen (BCMA) and interleukin-5 receptor alpha (IL5RA) in plasma. The largest increase in BCMA and IL5RA levels is mediated by the risk variant rs34562254-A at TNFRSF13B. While individuals with loss-of-function variants in TNFRSF13B develop B-cell immunodeficiency, rs34562254-A exerts a gain-of-function effect, increasing MM risk through amplified B-cell responses. Our results represent an analysis of genetic MM predisposition, highlighting causal mechanisms contributing to MM development.

10,906 European ancestry cases, 366,221 European ancestry controls

Chapter III

Study Statistics

Key metrics and study information

377127
Total Participants
GWAS
Study Type
No
Replicated
European
Ancestry
Sweden, Netherlands, U.S., Norway, Denmark, U.K., Germany, Iceland
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.